Ezetimibe/simvastatin combination not found to increase cancer risk, mortality
the ONA take:
According to a new study published in the American Journal of Cardiology, researchers have found that treatment with ezetimibe/simvastatin (Vytorin) is not linked with an elevated risk for developing cancer or an increased risk of cancer-related mortality.
Researchers identified 1,359 eligible patients for follow-up from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study so that they could investigate new incidences of cancer and total mortality over 21 months following the end of the SEAS trial. Of the 1,359 patients, 1,194 had no history of cancer cancer.
In that portion of patients, 12 patients who received ezetimibe/simvastatin had developed cancer and 22 patients that received placebo developed cancer in the 21-month follow-up (HR 0.55, 95% CI 0.27 - 1.11). During the same period, 43 patients who received ezetimibe/simvastatin and 33 who received placebo died (HR 1.29, 95% CI 0.82 - 2.03).
Results suggest that treatment with the lipid-lowering combination was not linked with an increased risk for developing cancer or dying from cancer during the 21-month follow-up to the SEAS trial. Numerous authors reported financial disclosures with Merck & Co., the manufacturer of Vytorin.
Ezetimibe/simvastatin (Vytorin) is not linked with an elevated risk for developing cancer.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Use of Aspirin, NSAIDs Correlates with Improved Overall Survival in Colorectal Cancer
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|